Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta‐analysis of randomized double‐blind controlled trials
- 31 May 2006
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 23 (10) , 1050-1056
- https://doi.org/10.1111/j.1464-5491.2006.01852.x
Abstract
Aims The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes.Methods We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double‐blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4–16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA1c) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random‐effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI).Results After a median duration of 12 weeks, the weighted mean post‐intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [−0.56 mmol/l (95% CI, −1.10 to −0.01); P for heterogeneity = 0.02]. The difference in post‐intervention HbA1c between magnesium supplementation groups and control groups was not significant [−0.31% (95% CI, −0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high‐density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low‐density lipoprotein (LDL) cholesterol and triglyceride.Conclusions Oral magnesium supplementation for 4–16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long‐term benefits and safety of magnesium treatment on glycaemic control remain to be determined.Keywords
This publication has 26 references indexed in Scilit:
- The Effect of Magnesium Supplementation in Increasing Doses on the Control of Type 2 DiabetesDiabetes Care, 1998
- The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjectsBritish Journal of Nutrition, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Hypomagnesemia in Type II Diabetes: Effect of a 3-Month Replacement TherapyDiabetes Care, 1995
- Magnesium and Ascorbic Acid Supplementation in Diabetes mellitusAnnals of Nutrition and Metabolism, 1995
- Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabeticsArchives of Family Medicine, 1994
- Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin- dependent (type II) diabetic patientsJournal of Clinical Endocrinology & Metabolism, 1994
- Improved Insulin Response and Action by Chronic Magnesium Administration in Aged NIDDM SubjectsDiabetes Care, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Safety and Effects of Potassium- and Magnesium-Containing Low Sodium Salt MixturesJournal of Cardiovascular Pharmacology, 1984